Company intelligence / Profile preview

Elegen

Menlo Park, California, United States

Ownership: Private
Development stage: Other

Overview

Elegen's ENFINIA DNA platform provides commercial, rapid, high-accuracy cell-free DNA synthesis, enabling faster and more reliable access to synthetic DNA for life sciences, pharma, healthcare, gene therapy, and synthetic biology applications. No clinical outcomes since this is a platform/manufacturing company, not a therapeutics developer.

Modalities: DNA synthesis technologySynthetic DNA
Industry: Non-Drug Biotech

Partnerships

GSKNutcracker Therapeutics

Beyond the preview

Go deeper on Elegen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elegen.

Explore the full profile